NCT07043751 is a Phase 1 clinical trial of TQB6411 injection in Advanced Malignant Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd..

What drugs are being tested in NCT07043751?

Interventions in NCT07043751: TQB6411 injection.

What condition does NCT07043751 study?

NCT07043751 studies Advanced Malignant Tumors.

Is NCT07043751 still recruiting?

NCT07043751 is currently recruiting now. Last updated 18 January 2026.

Last reviewed 2026-01-18 · How we verify

NCT07043751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Clinical Trial Evaluating the Tolerance, Pharmacokinetics and Preliminary Efficacy of Injection TQB6411 in Subjects With Advanced Malignant Tumors

Recruiting now Phase 1 Last updated 18 January 2026

What this trial tests

Phase 1 trial testing TQB6411 injection in Advanced Malignant Tumors in 216 participants. Currently enrolling.

Timeline

15 July 2025

Primary endpoint
1 December 2027

1 June 2028

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	216
Start date	15 July 2025
Primary completion	1 December 2027
Estimated completion	1 June 2028
Sites	19 locations across China

Drugs / interventions tested

TQB6411 injection — full drug profile →

Conditions studied

Advanced Malignant Tumors — all drugs for Advanced Malignant Tumors →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Dose-limiting toxicity
Time frame: Up to24 months
Dosage-limiting toxicity refers to any of the following events that researchers and sponsors believe to be related to the treatment of TQB6411 for injection (including positively related, likely related, and possible related) (except for special instructions, the degree of adverse events is evaluated in accordance with National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Adverse E
Maximum Tolerated Dose
Time frame: Up to24 months
Defined as the highest dose in less than 33% of subjects with dose-limiting toxicity (DLT).
Phase II recommended dose
Time frame: Up to24 months
The recommended dose for subsequent phase II studies will be determined based on Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), preliminary efficacy and safety.
Rate and severity of adverse events
Time frame: Up to24 months
Rate and severity of adverse events

Sponsor's own description

TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Malignant Tumors

Currently open trials in the same condition.

NCT07038005 — A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors · Phase 1 · recruiting
NCT07016490 — A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
NCT06877650 — First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting
NCT06764771 — A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors · Phase 1 · active not recruiting
NCT06223841 — A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors · Phase 1, PHASE2 · recruiting

Other Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07052097 — Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis · Phase 2 · completed
NCT06929195 — Clinical Trial to Evaluate the Tolerance of TQB2210 Injection · Phase 1 · completed
NCT06542614 — Treatment of Moderate to Severe Plaque Psoriasis · Phase 2 · completed
NCT06451640 — A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps · Phase 2 · completed
NCT06438783 — TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07043751 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Last refreshed: 18 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07043751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing